Insmed (INSM) Misses Q2 EPS by 70c ; Offers Guidance
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $120.00 -3.21%
Revenue Growth %: +253.0%
Financial Fact:
Net loss attributable to common stockholders: -37.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +253.0%
Financial Fact:
Net loss attributable to common stockholders: -37.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q2 EPS of ($1.94), $0.70 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $90.3 million versus the consensus estimate of $87.95 million.
GUIDANCE:
Insmed sees FY2024 revenue of $340-360 million, versus the consensus of $353.2 million.
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- OpenAI's Sam Altman to brief the UN Security Council next week - Reuters
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
